Literature DB >> 21704279

Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.

Roberta Melis1, Christiane Fauron, Gwendolyn McMillin, Elaine Lyon, Brian Shirts, Lindsey M Hubley, Patricia R Slev.   

Abstract

Recent genome-wide association studies have identified two host single-nucleotide polymorphisms (SNPs) near the IL28B gene (rs12979860 C/T and rs8099917 T/G) that are associated with sustained virological response in patients infected with the hepatitis C virus. Herein, we describe a rapid multiplexed dual-color fluorescence resonance energy transfer (FRET) probe assay that accurately genotypes for both SNPs simultaneously. A single-nucleotide extension assay was also developed for verification of genotypes. Agreement (100%) was observed in genotype calls between the FRET and single-nucleotide extension methods for both SNPs, yielding 100% analytical sensitivity and specificity. By using the FRET assay, 443 samples of varying ethnic backgrounds were genotyped and six different compound genotypes (rs12979860/rs8099917) were detected in whites, Asians, Middle Easterners, Hispanics, and African Americans, at the following frequencies: CC/TT (39.2%, 78.9%, 40.0%, 33.9%, and 16.8%), CT/TT (20.8%, 0%, 40%, 9.3%, and 37.0%), TT/TT (2.4%, 0%, 0%, 3.4%, and 35.3%), CT/TG (24.0%, 19.7%, 20%, 39.8%, and 3.4%), TT/TG (8.0%, 1.4%, 0%, 3.4%, and 5.9%), and TT/GG (5.6%, 0%, 0%, 10.2%, and 1.7%), respectively. The multiplexed FRET assay can be used to effectively genotype for both SNPs in a single tube, with high analytical sensitivity and specificity.
Copyright © 2011 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704279      PMCID: PMC3123790          DOI: 10.1016/j.jmoldx.2011.03.008

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

Review 1.  Side effects of therapy of hepatitis C and their management.

Authors:  Michael W Fried
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

2.  Discovering rare variants by use of melting temperature shifts seen in melting curve analysis.

Authors:  Elaine Lyon
Journal:  Clin Chem       Date:  2005-08       Impact factor: 8.327

3.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

4.  Lambda interferon inhibits hepatitis B and C virus replication.

Authors:  Michael D Robek; Bryan S Boyd; Francis V Chisari
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  The prevalence of hepatitis C virus infection in the United States, 1999 through 2002.

Authors:  Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

6.  HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Authors:  C Nelson Hayes; Mariko Kobayashi; Norio Akuta; Fumitaka Suzuki; Hiromitsu Kumada; Hiromi Abe; Daiki Miki; Michio Imamura; Hidenori Ochi; Naoyuki Kamatani; Yusuke Nakamura; Kazuaki Chayama
Journal:  Gut       Date:  2010-11-10       Impact factor: 23.059

7.  Simultaneous amplification, detection, and analysis of common mutations in the galactose-1-phosphate uridyl transferase gene.

Authors:  Mohamed Jama; Lesa Nelson; Genevieve Pont-Kingdon; Rong Mao; Elaine Lyon
Journal:  J Mol Diagn       Date:  2007-09-20       Impact factor: 5.568

8.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

9.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

View more
  8 in total

1.  Recent advances in management of the HIV/HCV coinfected patient.

Authors:  Cindy J Bednasz; Joshua R Sawyer; Anthony Martinez; Patrick G Rose; Samantha S Sithole; Holly R Hamilton; Farzia S Kaufman; Charles S Venuto; Qing Ma; Andrew Talal; Gene D Morse
Journal:  Future Virol       Date:  2015       Impact factor: 1.831

2.  Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico.

Authors:  Lilliana Morales-Vásquez; Edgar I Miranda-Avalo; José R Rodríguez-Medina; Yomarid Quiñones-Badillo; Juan Marqués-Lespier; José Muñoz-Acabá; Rafael Pastrana; Cynthia M Pérez-Cardona; Yasuhiro Yamamura; Esther A Torres
Journal:  P R Health Sci J       Date:  2014-12       Impact factor: 0.705

3.  Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Authors:  Shiho Miyase; Katsuki Haraoka; Yoshihiro Ouchida; Yuko Morishita; Shigetoshi Fujiyama
Journal:  J Gastroenterol       Date:  2012-03-02       Impact factor: 7.527

4.  Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients.

Authors:  Abdolvahab Alborzi; Tayebeh Hashempour; Javad Moayedi; Zahra Musavi; Gholamreza Pouladfar; Shahin Merat
Journal:  Med Microbiol Immunol       Date:  2017-02-18       Impact factor: 3.402

5.  Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.

Authors:  Emilie Estrabaud; Martine Lapalus; Philippe Broët; Kevin Appourchaux; Simon De Muynck; Olivier Lada; Michelle Martinot-Peignoux; Ivan Bièche; Dominique Valla; Pierre Bedossa; Patrick Marcellin; Michel Vidaud; Tarik Asselah
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

Review 6.  Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response.

Authors:  Yasuhiro Asahina; Mina Nakagawa; Sei Kakinuma; Mamoru Watanabe
Journal:  J Clin Transl Hepatol       Date:  2013-09-15

Review 7.  Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV.

Authors:  Stephen M Laidlaw; Lynn B Dustin
Journal:  Front Immunol       Date:  2014-10-31       Impact factor: 7.561

8.  Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19.

Authors:  Leonardo Sorrentino; Valentina Silvestri; Giuseppe Oliveto; Mirko Scordio; Federica Frasca; Matteo Fracella; Camilla Bitossi; Alessandra D'Auria; Letizia Santinelli; Lucia Gabriele; Alessandra Pierangeli; Claudio Maria Mastroianni; Gabriella d'Ettorre; Guido Antonelli; Antonio Caruz; Laura Ottini; Carolina Scagnolari
Journal:  Microorganisms       Date:  2022-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.